Table 2:

Disease progression markers in amnestic patients with MCI

Markers of Disease Progression	Characteristics	Procedure(s)^a	Approximate Cost (in US dollars)^b
Structural neuroimaging with vMRI	Medial temporal lobe and/or neocortical atrophy; white matter abnormalities may also be present	1) Noncontrast MRI brain CPT 70551	1) 437.20 (365.75^f+71.45^g)
Structural neuroimaging with vMRI		2) 3D quantitative segmental volume reporting and assessment^c CPT 76377	2) 82.68 (44.57^f+38.11^g)
FDG-PET	Temporoparietal hypometabolism	Brain imaging (PET) metabolic evaluation CPT 78608	1266.40 (1041.99^f+150ⁱ+74.41^g)
Amyloid imaging	Increased uptake in frontal, parietal, and/or temporal regions	PET imaging limited area CPT 78811	2721.83 (1041.99^f+1600ⁱ+79.84^g)
CSF amyloid	Decreased	1) CSF lumbar puncture CPT 62270	1) 242.58 (78.93^h+163.65^g)
CSF tau (total tau)	Increased	2) CSF analysis and interpretation^d CPT 83520	2) 1080
APOE ϵ4 carrier status	Dose-dependent effect (risk for AD: ϵ4/ϵ4 > ϵ3/ϵ4 > ϵ3/ϵ3 > ϵ3/ϵ2 > ϵ2/ϵ2)	1) Buccal swab or routine venipuncture CPT 36415	1) 3
APOE ϵ4 carrier status		2) APOE genotype analysis and interpretation^e CPT 81401	2) 500

Note:—APOE ϵ4 indicates apolipoprotein E4; CPT, Current Procedural Terminology; vMRI, volumetric-based MR imaging.
↵a Determined using data from the Centers for Medicare and Medicaid Services (www.cms.gov). For informational purposes only. Selected CPT code may vary.
↵b Determined, when possible, using National Payment Amount data from the Centers for Medicare and Medicaid Services (www.cms.gov). For informational purposes only. Payment amount varies by location.
↵c Using NeuroQuant (http://www.cortechs.net/products/neuroquant.php).
↵d Using the ADmark Phospho-Tau/Total-Tau/Ab42 CSF Analysis & Interpretation (Symptomatic) test (http://www.athenadiagnostics.com/content/test-catalog/find-test/service-detail/q/id/311).
↵e Using the ADmark ApoE Genotype Analysis & Interpretation (Symptomatic) (http://www.athenadiagnostics.com/content/test-catalog/find-test/service-detail/q/id/35).
↵f Approximate technical charge.
↵g Approximate professional charge.
↵h Approximate facility price.
↵i Approximate ligand price.